Resolutions at Senzime AB’s (publ) extraordinary general meeting

A.  Resolution on directed share issue (No 1)

The general meeting resolved to issue new shares in accordance with the proposal by the board of directors. The resolution entails an increase of the Company’s share capital with not more than SEK 447,917.0004 by an issue of not more than 3,583,336 new shares following the terms and conditions as set out below.

The right to subscribe for new shares shall, with deviation from the shareholders pre-emption rights, belong to the following persons/companies:

Subscriber                                                Number of shares   Subscription amount

Segulah Venture AB                                 2,500,000 shares            SEK 15,000,000

Mikael Lindskog                                           250,000 shares              SEK 1,500,000

Jerry Fredriksson                                         250,000 shares              SEK 1,500,000

Margareta Nilsson                                        133,334 shares                 SEK 800,004

Anna Manhusen                                           133,334 shares                 SEK 800,004

Crafoordska stiftelsen                                  133,334 shares                 SEK 800,004

Carl Rosenblad                                            100,000 shares                SEK 600,000

Lennart Nilsson                                              83,334 shares                 SEK 500,004

(via wholly-owned company)                                               

Total:                                                         3,583,336 shares            SEK 21,500,016

The reason for the deviation from the shareholders’ pre-emption rights is to acquire necessary funds to the Company, tie strategically important investors to the Company, strengthen the ownership base of the Company in order to increase the chances for a successful commercialization of the Company's products and additionally to accomplish a time and cost effective new issue of shares.

Subscription shall be made through payment not later than 7 March 2018. The board of directors shall have the right to extend the subscription and payment period.

The new shares are issued at a price of SEK 6 per share, which at full subscription means that the Company will receive SEK 21,500,016 (prior to issue costs).

The subscription price for the new shares has been negotiated with Segulah Venture AB and corresponds to a discount of 8 percent in comparison with the share weighted average price on the 10 latest trading days. Market conditions have been ensured through the mentioned negotiation and taking into account current market situation.

The new shares entitle to dividends for the first time on the first record date for dividend that take place after the issue of new shares has been registered with the Swedish Companies Registration Office and been recorded in the share register kept by Euroclear Sweden AB.

B. Resolution on directed share issue (No 2)

The general meeting resolved to issue new shares in accordance with the proposal by the board of directors. The resolution entails an increase of the Company’s share capital with not more than SEK 72,916.7501 by an issue of not more than 583,334 new shares following the terms and conditions as set out below.

The right to subscribe for new shares shall, with deviation from the shareholders pre-emption rights, belong to the following persons:

Subscriber                                                Number of shares   Subscription amount

Ulf Lindskog                                                 400,000 shares              SEK 2,400,000

Adam Dahlberg                                            183,334 shares              SEK 1,100,004

Total:                                                            583,334 shares              SEK 3,500,004

The terms and conditions of the share issue are the same as set out for the directed share issue under section A above.

All resolutions at the annual general meeting were adopted with the requisite majority.

For further information, please contact:

Lena Söderström, CEO of Senzime AB

Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

————————————

Senzime AB (publ)

Board of directors

TO THE EDITORS  

About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime.www.senzime.com